The PE Ratio as of December 2024 (TTM) for Cerevel Therapeutics Holdings, Inc. (CERE) is -16.47

According to Cerevel Therapeutics Holdings, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -16.47. This represents a change of 31.81% compared to the average of -12.49 of the last 4 quarters.

Cerevel Therapeutics Holdings, Inc. (CERE) Historical PE Ratio (quarterly & annually)

How has CERE PE Ratio performed in the past?

The mean historical PE Ratio of Cerevel Therapeutics Holdings, Inc. over the last ten years is -9.20. The current -16.47 PE Ratio has changed 17.80% with respect to the historical average. Over the past ten years (40 quarters), CERE's PE Ratio was at its highest in in the February 2012 quarter at 24.91. The PE Ratio was at its lowest in in the February 2001 quarter at -7123.71.

Cerevel Therapeutics Holdings, Inc. (CERE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cerevel Therapeutics Holdings, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cerevel Therapeutics Holdings, Inc. (CERE) Average PE Ratio

How has CERE PE Ratio performed in the past?

The current PE Ratio of Cerevel Therapeutics Holdings, Inc. (CERE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Cerevel Therapeutics Holdings, Inc. (CERE) PE Ratio vs. Peers

How is CERE’s PE Ratio compared to its peers?

Cerevel Therapeutics Holdings, Inc.’s PE Ratio is less than Avidity Biosciences, Inc. (-13.92), less than Revolution Medicines, Inc. (-12.93), less than Day One Biopharmaceuticals, Inc. (-14.55), less than SpringWorks Therapeutics, Inc. (-10.09), less than Ventyx Biosciences, Inc. (-1.09), greater than Nuvalent, Inc. (-24.55), less than Travere Therapeutics, Inc. (-3.80), less than Structure Therapeutics Inc. (-12.76), less than Monte Rosa Therapeutics, Inc. (-4.90), less than Design Therapeutics, Inc. (-7.36), less than Werewolf Therapeutics, Inc. (-1.10), less than Ikena Oncology, Inc. (-1.35), less than Stoke Therapeutics, Inc. (-6.20), less than Apellis Pharmaceuticals, Inc. (-16.45), less than Terns Pharmaceuticals, Inc. (-5.24), greater than Blueprint Medicines Corporation (-44.71), less than IGM Biosciences, Inc. (-1.80), less than Cullinan Oncology, Inc. (-4.82), less than Mineralys Therapeutics, Inc. (-3.92),

Build a custom stock screener for Cerevel Therapeutics Holdings, Inc. (CERE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cerevel Therapeutics Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cerevel Therapeutics Holdings, Inc. (CERE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cerevel Therapeutics Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.